---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-033464"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:18:12.959473+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tempest reports FY2023 net loss $29.5M; positive Phase 1b/2 HCC data for TPST-1120

## Summary
- Net loss $29.5M ($1.91/sh) vs $35.7M in 2022; cash $39.2M, runway into Q2 2025.
- TPST-1120 triplet arm: 30% cORR vs 13.3% control; OS HR 0.59 favoring TPST-1120 in first-line HCC.
- Plan to advance TPST-1120 into pivotal Phase 3 in HCC; TPST-1495 into Phase 2 FAP (pending NCI).
- R&D expenses down to $17.5M from $22.5M, primarily due to lower CRO costs.

## SEC filing metadata
- accession: 0000950170-24-033464
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000095017024033464/0000950170-24-033464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000095017024033464/tpst-20240319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-033464
- JSON: https://secwatch.observer/filing/0000950170-24-033464.json
- Plain text: https://secwatch.observer/filing/0000950170-24-033464.txt

## Key facts
- Earnings Releases
  Tempest Therapeutics, Inc. reported financial results for year ended December 31, 2023.
  - Period: year ended December 31, 2023
  - Result: reported results
  source text: On March 19, 2024, Tempest Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023 and other business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000095017024033464/0000950170-24-033464-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.